Genetic, Phenotypic, and Clinical Heterogeneity of NPM1-Mutant Acute Myeloid Leukemias

Clinical relevance of mutant NPM1 and CEBPA in patients with acute myeloid leukaemia – preliminary report

AIM OF THE STUDY Mutant NPM1 and CEBPA have been reported in patients with acute myeloid leukaemia (AML) and intermediate cytogenetic risk, and they appear to be associated with characteristic demographic and laboratory data, as well as clinical outcome. The objective of the study was to assess the clinical relevance of NPM1 and CEBPA mutations in AML. MATERIAL AND METHODS This retrospective ...

The Impact of Molecular Genetic in Acute Myeloid Leukemias

The discovery and application of advanced molecular techniques, such as gene and microRNA expression profiling, whole genome and exome sequencing and methylation assays, allowed for the identification of recurrent molecular abnormalities in acute myeloid leukemia (AML) that have revolutionized our understanding of the genetic landscape of the disease. Moreover, these modalities have emerged as ...

Classification of acute myeloid leukemias

Therapy-Related Acute Myeloid Leukemias

Therapy-related acute myeloid leukemia (t-AML) is a heterogeneous group of myeloid neo‐ plasms occurring as an overwhelming complication in patients receiving previous cytotoxic chemotherapy and/or radiation therapy used to treat haematopoietic or solid malignancies or associated with immunosuppressive treatment for non-neoplastic rheumatologic/autoim‐ mune diseases or solid organ transplantati...

Genetic Testing for FLT3 and NPM1, and CEBPA Mutations in Acute Myeloid Leukemia